Want to see CTXR full AI Analyst Report?
Top Page
Citius Pharmaceuticals
(NASDAQ:CTXR)
Select Model
Select Model
Rating:54Neutral
Price Target:
$0.63
▲(21.92% Upside)
Action:Reiterated
Date:08/05/26
The score is held down primarily by weak financial performance driven by large ongoing losses and significant cash burn, even though gross margins are strong and leverage is low. Offsetting this, technicals show improving near-term momentum, and recent corporate events are constructive with reported LYMPHIR launch traction and positive early clinical data. Valuation support is limited due to a negative P/E and no dividend yield provided.
Positive Factors
High gross margins and initial revenue growth
Sustained ~68% gross margins and an increase in TTM revenue to ~$5.6M indicate attractive unit economics for marketed products. If commercial traction continues, high margins support scalable profitability as volumes grow, improving the long-term leverage of incremental revenue over fixed costs.
Negative Factors
Large cash burn
Operating and free cash flow near -$31.6M TTM is a material structural weakness: the company must raise capital or secure new financing to sustain operations. Persistent negative cash flow constrains strategic flexibility, increases dilution risk, and forces prioritization of programs over multi-front investment.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins and initial revenue growth
Sustained ~68% gross margins and an increase in TTM revenue to ~$5.6M indicate attractive unit economics for marketed products. If commercial traction continues, high margins support scalable profitability as volumes grow, improving the long-term leverage of incremental revenue over fixed costs.
Read all positive factors
Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.65M
Dividend YieldN/A
Average Volume (3M)285.32K
Price to Earnings (P/E)―
Beta (1Y)2.44
Revenue GrowthN/A
EPS Growth55.15%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.57
Shares Outstanding27,452,570
10 Day Avg. Volume442,850
30 Day Avg. Volume285,317
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.11
Revenue Forecast (FY)$49.56M
Citius Pharmaceuticals Business Overview & Revenue Model
Company Description
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cance...
How the Company Makes Money
null...
Citius Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.10M | -214.25K | -209.61K | -194.32K | -179.68K | -164.87K |
| EBITDA | -55.93M | -38.20M | -38.64M | -31.77M | -32.88M | -22.88M |
| Net Income | -46.20M | -37.43M | -39.14M | -32.54M | -33.64M | -23.13M |
Balance Sheet | ||||||
| Total Assets | 132.54M | 130.94M | 116.65M | 103.61M | 114.00M | 142.43M |
| Cash, Cash Equivalents and Short-Term Investments | 4.59M | 4.25M | 3.25M | 26.48M | 41.71M | 70.07M |
| Total Debt | 808.16K | 1.81M | 262.87K | 481.25K | 678.23K | 855.47K |
| Total Liabilities | 63.46M | 53.41M | 42.55M | 12.18M | 10.57M | 9.65M |
| Stockholders Equity | 61.54M | 67.55M | 70.08M | 90.83M | 102.83M | 132.18M |
Cash Flow | ||||||
| Free Cash Flow | -31.60M | -26.55M | -28.20M | -29.06M | -28.36M | -64.26M |
| Operating Cash Flow | -31.60M | -26.55M | -28.20M | -29.06M | -28.36M | -24.25M |
| Investing Cash Flow | -10.75M | -5.75M | -5.00M | 0.00 | 0.00 | -40.01M |
| Financing Cash Flow | 46.91M | 33.30M | 9.97M | 13.83M | 0.00 | 120.47M |
Citius Pharmaceuticals Technical Analysis
Positive
0.52
Price Trends
0.57
Positive
0.66
Negative
0.85
Negative
Market Momentum
<0.01
Negative
57.69
Neutral
57.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Positive. The current price of 0.52 is below the 20-day moving average (MA) of 0.55, below the 50-day MA of 0.57, and below the 200-day MA of 0.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.69 is Neutral, neither overbought nor oversold. The STOCH value of 57.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTXR.
Citius Pharmaceuticals Risk Analysis
Citius Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $15.65M | -0.22 | -67.42% | ― | ― | 55.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.69M | -1.46 | -47.86% | ― | -93.71% | 23.89% | |
47 Neutral | $13.70M | -1.65 | -5515.09% | ― | 3581.22% | 98.63% | |
45 Neutral | $17.48M | -1.08 | -66.69% | ― | -45.52% | -94.82% | |
44 Neutral | $18.27M | -1.17 | 763.44% | ― | ― | ― | |
41 Neutral | $14.62M | -0.26 | -1335.64% | ― | ― | 66.47% |
* Healthcare Sector Average
CTXR
Citius Pharmaceuticals
0.62
-0.73
-53.93%
BLRX
Bioline RX Ltd Sponsored ADR
2.76
-1.13
-29.05%
PTN
Palatin Technologies
8.01
0.41
5.39%
DARE
Daré Bioscience
1.34
-1.06
-44.17%
LPCN
Lipocine
2.13
-0.95
-30.84%
KALA
KALA BIO
0.74
-384.26
-99.81%
Citius Pharmaceuticals Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Citius Oncology reports strong LYMPHIR U.S. launch momentum
Positive
Aug 5, 2026
On August 5, 2026, Citius Oncology reported strong commercial momentum for LYMPHIR’s U.S. launch, highlighting rapid uptake among treatment centers and wholesalers. The number of new institutions ordering LYMPHIR rose 78% quarter over quarte...
Business Operations and StrategyProduct-Related Announcements
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers
Positive
Jun 1, 2026
On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in recurrent or refractory gynecologic malignancies, presented May 30, 2026 at the ...
Business Operations and StrategyPrivate Placements and Financing
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Positive
May 8, 2026
On May 4, 2026, Citius Pharmaceuticals and its majority-owned unit Citius Oncology amended a 2024 promissory note originally issued by Citius Oncology to the parent in the principal amount of about $3.8 million, aligning its payment and maturity t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.